These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10147286)

  • 1. Third generation cephalosporins in the parenteral to oral switch.
    Rimmer D
    Pharmacoeconomics; 1994; 5(Suppl 2):27-33. PubMed ID: 10147286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral cephalosporins for use in a parenteral-to-oral switch programme.
    Rimmer DM
    Infection; 1995; 23 Suppl 2():S87-90. PubMed ID: 8537139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of cephalosporins for hospital formularies.
    Wilson WR
    Diagn Microbiol Infect Dis; 1995; 22(1-2):129-34. PubMed ID: 7587026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefixime for switch therapy.
    Hamilton-Miller J
    Chemotherapy; 1998 Sep; 44 Suppl 1():24-7. PubMed ID: 9797420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the use of cefixime for switch therapy.
    Low DE
    Infection; 1995; 23 Suppl 2():S91-4. PubMed ID: 8537140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential therapy with intravenous and oral cephalosporins.
    Janknegt R; van der Meer JW
    J Antimicrob Chemother; 1994 Jan; 33(1):169-77. PubMed ID: 8157558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Place of parenteral cephalosporins in the ambulatory setting: clinical evidence.
    Nathwani D
    Drugs; 2000; 59 Suppl 3():37-46; discussion 47-9. PubMed ID: 10845412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cefixime, the first oral third-generation cephalosporin].
    Roche G
    Presse Med; 1989 Oct; 18(32):1541-4. PubMed ID: 2530527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparative evaluation of oral and parenteral cephalosporins in inhibiting the growth of bacteria pathogenic to the periodontium].
    Fanali S; Paolantonio M; Di Benedetto A; Bascelli A; Tetè S; Piccolomini R
    Minerva Stomatol; 1990 Aug; 39(8):637-40. PubMed ID: 2287333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins.
    Tice AD
    Drugs; 2000; 59 Suppl 3():29-35; discussion 47-9. PubMed ID: 10845411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbation of chronic bronchitis.
    Lorenz J
    Chemotherapy; 1998 Sep; 44 Suppl 1():15-8. PubMed ID: 9797418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic considerations in the use of third-generation oral cephalosporins.
    Chambers ST; Murdoch DR; Pearce MJ
    Pharmacoeconomics; 1995 May; 7(5):416-27. PubMed ID: 10155329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins.
    Davey PG; Malek M
    Pharmacoeconomics; 1994; 5(Suppl 2):11-9. PubMed ID: 10147284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use, misuse, and cost of parenteral cephalosporins at a county hospital.
    Appleby DH; John JF
    South Med J; 1980 Nov; 73(11):1473-5. PubMed ID: 7444511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Peroral preparations of cephalosporin antibiotics].
    Babálová M; Blahová J; Hupková M; Krcméry V
    Cas Lek Cesk; 1994 Jan; 133(1):22-4. PubMed ID: 8111831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages.
    Esposito S
    Drugs; 2000; 59 Suppl 3():19-28; discussion 47-9. PubMed ID: 10845410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci.
    Tapsall JW
    Sex Transm Infect; 2009 Aug; 85(4):256-8. PubMed ID: 19261600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost, motion, and time studies comparing a new cephalosporin admixture system.
    Turco SJ
    Hosp Pharm; 1982 Dec; 17(12):653-8. PubMed ID: 10257925
    [No Abstract]   [Full Text] [Related]  

  • 19. Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children.
    Memon IA; Billoo AG; Memon HI
    South Med J; 1997 Dec; 90(12):1204-7. PubMed ID: 9404906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins.
    Smyth ET; Barr JG; O'Neill CA; Hogg GM
    Pharmacoeconomics; 1995 Dec; 8(6):541-50. PubMed ID: 10160082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.